Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Left ventricular hypertrophy in hypertension: its arrhythmogenic potential.

Literature DB >> 15657259

Left ventricular hypertrophy in hypertension: its arrhythmogenic potential.

Thomas Kahan¹, Lennart Bergfeldt.

Abstract

Entities: Disease

Mesh：

Year: 2005 PMID： 15657259 PMCID： PMC1768675 DOI： 10.1136/hrt.2004.042473

Source DB: PubMed Journal: Heart ISSN： 1355-6037 Impact factor: 5.994

× No keyword cloud information.

19 in total

Review 1. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors: Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal: Am J Med Date: 2003-07 Impact factor: 4.965

2. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease.

Authors: C G Brilla; R C Funck; H Rupp
Journal: Circulation Date: 2000-09-19 Impact factor: 29.690

3. Prognostic implications of left ventricular hypertrophy.

Authors: B A Vakili; P M Okin; R B Devereux
Journal: Am Heart J Date: 2001-03 Impact factor: 4.749

4. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial.

Authors: Lisa Kurland; Håkan Melhus; Julia Karlsson; Thomas Kahan; Karin Malmqvist; Peter Ohman; Fredrik Nyström; Anders Hägg; Lars Lind
Journal: J Hypertens Date: 2002-04 Impact factor: 4.844

Review 5. New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias.

Authors:
Journal: Eur Heart J Date: 2001-12 Impact factor: 29.983

6. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA).

Authors: Karin Malmqvist; Thomas Kahan; Magnus Edner; Lennart Bergfeldt
Journal: Am J Cardiol Date: 2002-11-15 Impact factor: 2.778

Review 7. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy.

Authors: Daniel J Lips; Leon J deWindt; Dave J W van Kraaij; Pieter A Doevendans
Journal: Eur Heart J Date: 2003-05 Impact factor: 29.983

8. Irbesartan reduces QT dispersion in hypertensive individuals.

Authors: P O Lim; M Nys; A A Naas; A D Struthers; M Osbakken; T M MacDonald
Journal: Hypertension Date: 1999-02 Impact factor: 10.190

9. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy.

Authors: Markus P Schlaich; David M Kaye; Elisabeth Lambert; Marcus Sommerville; Flora Socratous; Murray D Esler
Journal: Circulation Date: 2003-07-07 Impact factor: 29.690

Review 10. The importance of left ventricular hypertrophy in human hypertension.

Authors: T Kahan
Journal: J Hypertens Suppl Date: 1998-09

43 in total

1. Factors Contributing to Development and Reversal of LVH: A Pilot Study.

Authors: Prasanna Kumar Hassan Ramaswamy; M Bhanukumar; Basavanagowdappa Hathur; K C Shashidhara; K M Srinath
Journal: J Clin Diagn Res Date: 2016-05-01

2. Inter-relationship between electrocardiographic left ventricular hypertrophy and QT prolongation as predictors of increased risk of mortality in the general population.

Authors: Elsayed Z Soliman; Amit J Shah; Andrew Boerkircher; Yabing Li; Pentti M Rautaharju
Journal: Circ Arrhythm Electrophysiol Date: 2014-04-24

3. A History of Asthma From Childhood and Left Ventricular Mass in Asymptomatic Young Adults: The Bogalusa Heart Study.

Authors: Dianjianyi Sun; Tiange Wang; Yoriko Heianza; Jun Lv; Liyuan Han; Felicia Rabito; Tanika Kelly; Shengxu Li; Jiang He; Lydia Bazzano; Wei Chen; Lu Qi
Journal: JACC Heart Fail Date: 2017-06-26 Impact factor: 12.035

Review 4. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy.

Authors: Chike C Nwabuo; Ramachandran S Vasan
Journal: Curr Hypertens Rep Date: 2020-02-03 Impact factor: 5.369

5. The relationship between R wave peak time and left ventricular mass index in patients with end-stage renal disease on hemodialysis.

Authors: Macit Kalçık; Mucahit Yetim; Tolga Doğan; Barış Eser; İbrahim Doğan; Lütfü Bekar; Oğuzhan Çelik; Yusuf Karavelioğlu
Journal: Int Urol Nephrol Date: 2019-09-30 Impact factor: 2.370